Smith Group Asset Management’s CareDx CDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-60
Closed -$3K 292
2021
Q4
$3K Hold
60
﹤0.01% 352
2021
Q3
$4K Hold
60
﹤0.01% 351
2021
Q2
$5K Hold
60
﹤0.01% 342
2021
Q1
$4K Sell
60
-1,590
-96% -$123K ﹤0.01% 311
2020
Q4
$120K Hold
1,650
0.01% 200
2020
Q3
$63K Hold
1,650
﹤0.01% 210
2020
Q2
$58K Sell
1,650
-30
-2% -$854 ﹤0.01% 200
2020
Q1
$37K Hold
1,680
﹤0.01% 257
2019
Q4
$36K Hold
1,680
﹤0.01% 298
2019
Q3
$38K Buy
+1,680
New +$46.5K ﹤0.01% 294

Other funds holding CDNA

Smith Group Asset Management's CDNA Position: Q1 2022 in Review

Smith Group Asset Management sold out of CareDx (CDNA) in Q1 2022, closing a stake of 60 shares — an estimated $3K sold.

Smith Group Asset Management first reported a position in CDNA in Q3 2019 and held it in 10 quarters. The position peaked at $120K in Q4 2020. 213 funds tracked by Wall St. Rank hold CDNA as of Q1 2022.

  • Smith Group Asset Management reported no remaining CareDx position as of Q1 2022 after selling out during the quarter.
  • Smith Group Asset Management sold 60 CareDx shares in Q1 2022, an estimated $3K.
  • Smith Group Asset Management first reported a position in CareDx in Q3 2019 and held it in 10 quarters.
  • Smith Group Asset Management's CareDx position peaked at $120K in Q4 2020.
  • 213 funds tracked by Wall St. Rank held CareDx as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.